Lifeline Cell Technology Products Being Used As Models for Drug
Testing DiscoveryBioMed,
Inc. has agreed to move forward with a "service" contract for
primary human cell bioassay testing for its first commercial client, Lifeline
Cell Technology, Inc., a wholly owned subsidiary of International
Stem Cell Corporation (OTCBB:
ISCO).
"This is a mutually beneficial relationship between two companies that
believe in the development, use, and sale of human cells as the most
important and biologically relevant reagents for experimental systems,"
said Dr. Erik Schwiebert, CEO of DBM, Inc. "Lifeline Cell Tech is also
our first commercial client and these contracts provide a wonderful
opportunity for our company to generate knowledge about human cell
physiology as well as early revenue."
"We agree that human cells are critically important in-vitro
models to assure drug safety and conduct basic research," said ISCO
President and Lifeline Cell Technology CEO Jeffrey Janus.
"DiscoveryBioMed's proven expertise in assay development combined with
Lifeline's expertise in producing optimized human adult and stem cell
products will certainly result in powerful research tools."
In addition to these introductory interactions, DBM and Lifeline Cell
Tech are developing a mutual SBIR grant proposal on the use of multiple
human cell cultures derived from different tissues as an important in
vitro platform for testing pollutant, candidate therapeutics and
existing drugs for toxicity against cells in a variety of human tissues.
ABOUT DISCOVERYBIOMED, INC.
DiscoveryBioMed, Inc. is a life sciences and biotechnology company that
engages in R&D and services work in cell engineering and production and
drug discovery. The company is located within Innovation Depot in
Birmingham. Using physiologically relevant cell culture models
preferably derived from normal and diseased adult human cells and
tissues, it focuses on finding therapeutic compounds for a variety of
human diseases. It also applies this custom human cell-based approach to
its "fee-for-service" support to researchers in allied areas and
currently serves clients both locally in Alabama as well as in 8 other
states in the US currently. For more information, visit the DBM website
at www.discoverybiomed.com.
ABOUT INTERNATIONAL STEM CELL
CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first Parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will minimize immune rejection after transplantation into hundreds
of millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
For more news and information on International Stem Cell
Corporation, please visit www.IRGnews.com/coi/ISCO
where you can find the CEO's video, a fact sheet on the company,
investor presentations, and more.
FORWARD-LOOKING STATEMENTS Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
DiscoveryBioMed, Inc. Erik Schwiebert, Ph.D., CEO erik@discoverybiomed.com or International
Stem Cell Corporation Jeffrey Janus, President jjanus@intlstemcell.com 760-940-6383 or The
Investor Relations Group 212-825-3210 Investor Relations: Adam
S. Holdsworth aholdsworth@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |